Today, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the adjuvant treatment of patients with melanoma that has involvement of lymph nodes or metastatic disease, and who have undergone complete resection.
Today, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the adjuvant treatment of patients with melanoma that has involvement of lymph nodes or metastatic disease, and who have undergone complete resection. Nivolumab is the first and only anti-programmed death (PD)-1 immune checkpoint inhibitor that is approved for adjuvant treatment of melanoma, and is indicated for both BRAF mutant and wild type patients.
In the phase 3 CheckMate-238 trial, nivolumab significantly improved recurrence-free survival (RFS) versus ipilimumab (Yervoy, Bristol-Myers Squibb), in patients with stage III/C or stage IV melanoma after surgery. This result was observed across multiple subgroups, including both BRAF mutant and BRAF wild-type patients.
“Today’s approval builds on our leadership in melanoma, offering physicians a new option with the potential to change the course of the disease through earlier intervention. Opdivo is the first PD-1 inhibitor approved as an adjuvant treatment for any cancer,” said Johanna Mercier, head, US commercial, Bristol-Myers Squibb. “Our decision to study Opdivo versus Yervoy—an established standard of care with a proven survival benefit—represents our relentless pursuit to bring more effective treatments to patients.”
Opdivo demonstrated an 18-month RFS rate of 66.4% (95% CI: 61.8 to 70.6) compared with 52.7% for Yervoy (95% CI: 47.8 to 57.4), with the median RFS not yet determined in either group. Opdivo reduced the risk of disease recurrence by 35% versus Yervoy (hazard ratio [HR]: 0.65; 95% CI: 0.53 to 0.80; p <0.0001).
In September 2017, nivolumab received “Breakthrough Therapy Designation” from the FDA for the adjuvant treatment of patients with high-risk, fully resected melanoma.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More